KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Travere Therapeutics (TVTX) EBT Margin (2016 - 2025)

Travere Therapeutics (TVTX) has disclosed EBT Margin for 13 consecutive years, with 8.28% as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, EBT Margin rose 7241.0% year-over-year to 8.28%, compared with a TTM value of 10.04% through Dec 2025, up 12741.0%, and an annual FY2025 reading of 10.04%, up 12741.0% over the prior year.
  • EBT Margin was 8.28% for Q4 2025 at Travere Therapeutics, down from 64.28% in the prior quarter.
  • Across five years, EBT Margin topped out at 64.28% in Q3 2025 and bottomed at 348.94% in Q1 2022.
  • Average EBT Margin over 5 years is 155.38%, with a median of 120.76% recorded in 2021.
  • The sharpest move saw EBT Margin surged 29558bps in 2021, then plummeted -34777bps in 2022.
  • Year by year, EBT Margin stood at 56.1% in 2021, then tumbled by -620bps to 291.67% in 2022, then skyrocketed by 33bps to 196.47% in 2023, then surged by 59bps to 80.68% in 2024, then surged by 90bps to 8.28% in 2025.
  • Business Quant data shows EBT Margin for TVTX at 8.28% in Q4 2025, 64.28% in Q3 2025, and 11.13% in Q2 2025.